IP Library Granted Patent US 7,829,277
Granted Patent B2
US 7,829,277 · App. 10/591,097 · Granted Nov 9, 2010

Methods for identifying compounds that suppress chemically-induced carcinogenesis

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,829,277
App. No.
10/591,097
Granted
Nov 9, 2010
Kind
B2
Abstract

Gene expression profiles produced in response to lunasin exposure, wherein such gene expression profiles correlate with anti-neoplastic activity, methods for using such expression profiles for screening potential anti-neoplastic agents, and methods for treatment and monitoring of a subject having a neoplastic disease.

Claims (6)

1. A method for identifying a test compound that has the property of suppressing chemically-induced carcinogenesis in mammalian cells, the method comprising: a) providing RWPE-1 and RWPE-2 cells, b) measuring expression of a set of genes in the RWPE-1 and the RWPE-2 cells wherein the set of genes comprises at least the genes: ADAM9, BUB1B, CD46, GJA1, HIF1A, ITGB1, LAMB1, MAD2L1, the gene encoding FLJ20372, Formin binding protein 3, PSMC6, RANBP2, CSPG6, SP3, THBS1, TTK, PRKAR1A, TOB1, and Acidic leucine-rich nuclear phosphoprotein 32 family, member E, c) exposing RWPE-1 and RWPE-2 cells to the test compound, d) re-measuring the expression of the genes by the cells after exposure to the test compound, and e) comparing the expression of the genes in RWPE-1 cells with the expression of the genes in RWPE-2 cells, wherein a coordinated increase in expression of at least two-fold of all of the above genes in RWPE-1 cells but not in RWPE-2 cells following exposure to the test compound indicates that the test compound has the property of suppressing chemically-induced carcinogenesis in mammalian cells.

2. The method of claim 1 wherein the degree of increase of expression of the genes is measured using a weighted average.

3. The method of claim 1 wherein the set of genes further comprises at least one of the genes selected from the group consisting of ERBB2IP, BNIP3 and USP1.

4. The method of claim 1 wherein the set of genes comprises genes selected from the group consisting of: genes that regulate apoptosis, genes involved in suppression of cell proliferation, mitotic check point genes, genes involved in protein degradation, and genes that up-regulate the gap junction proteins.

5. The method of claim 1 wherein gene expression is measured using an array comprising a substrate and a plurality of polynucleotide probes affixed to the substrate.

6. The method of claim 5 wherein the array comprises a plurality of polynucleotide probes that are specifically complementary to said genes.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 20, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025664/0261 →
CONFIRMATORY LICENSE Recorded Jun 18, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024561/0907 →
Continuity (3)
Provisional Application 6054948700 · Mar 1, 2004
Provisional Application 6062121700 · Oct 21, 2004
Related Publication 20080003567A1 · Jan 3, 2008